As of 2024-12-15, the Intrinsic Value of Halozyme Therapeutics Inc (HALO) is
64.53 USD. This HALO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 48.00 USD, the upside of Halozyme Therapeutics Inc is
34.40%.
The range of the Intrinsic Value is 43.65 - 115.37 USD
64.53 USD
Intrinsic Value
HALO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
43.65 - 115.37 |
64.53 |
34.4% |
| DCF (Growth 10y) |
69.84 - 170.19 |
99.23 |
106.7% |
| DCF (EBITDA 5y) |
66.92 - 84.07 |
76.01 |
58.3% |
| DCF (EBITDA 10y) |
89.25 - 119.49 |
104.25 |
117.2% |
| Fair Value |
77.12 - 77.12 |
77.12 |
60.66% |
| P/E |
53.19 - 150.53 |
106.11 |
121.1% |
| EV/EBITDA |
45.03 - 72.53 |
58.11 |
21.1% |
| EPV |
12.43 - 19.09 |
15.76 |
-67.2% |
| DDM - Stable |
24.17 - 68.01 |
46.09 |
-4.0% |
| DDM - Multi |
39.97 - 88.15 |
55.08 |
14.8% |
HALO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
6,107.04 |
| Beta |
1.34 |
| Outstanding shares (mil) |
127.23 |
| Enterprise Value (mil) |
7,456.88 |
| Market risk premium |
4.60% |
| Cost of Equity |
10.51% |
| Cost of Debt |
4.25% |
| WACC |
9.14% |